MannKind | MNKD - Операционный доход





Операционный доход Изменить Дата
Adma Biologics USD 62.75M 11.74M 2025-12
BioCryst Pharmaceuticals USD 260.38M 230.79M 2025-12
Eli Lilly USD 9.78B 792M 2026-03
Halozyme Therapeutics USD -61.77M 26.64M 2026-03
Insmed USD -200.28M 49.43M 2026-03
Karyopharm Therapeutics USD -17.84M 13.44M 2025-12
MacroGenics USD -12.1M 30.74M 2025-12
MannKind USD -76.99M 7.75M 2026-03
Merck USD -1.88B 8.12B 2026-03
Minerva Neurosciences USD -21.85M 17.48M 2024-12
Novavax USD 20.94M 100.32M 2025-12
Novo Nordisk DKK 5.18B 33.61B 2025-06
Pfizer USD 4.99B 340M 2026-03
Sanofi EUR 1.94B 239M 2026-03
Xencor USD -77.86M 24.23M 2026-03